The allowed claims encompass GeoVax’s Mucin 1 (MUC1) tumor-associated antigen immunotherapy candidate, MVA-VLP-MUC1. The Company uses its MVA-VLP vaccine platform to express abnormal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback